降钙素原指导的抗生素停用在重症成人中的死亡率影响:系统评价与Meta分析
该系统评价与Meta分析纳入16项随机对照试验(5158例随机,5000例分析),评估降钙素原指导的抗生素停用对重症成人死亡率及抗生素使用时长的影响。主要结果:降钙素原指导组死亡率降低(RR 0.89,95%CI 0.83-0.97,I²=0%,低确定性),抗生素使用时长缩短(均数差1.31天,95%CI -2.27至-0.35,I²=93%,低确定性)。但死亡率获益在脓毒症亚组、无企业赞助研究、高方案依从性研究及不含C反应蛋白的算法中未观察到。结论认为该证据为低确定性且高偏倚风险,主要见于方案依从性不高及降钙素原联合C反应蛋白算法的研究。
要点
- 在重症成人中,降钙素原指导的抗生素停用与死亡率降低相关(16项RCT,RR 0.89,95%CI 0.83-0.97,I²=0%,低确定性)。
- 降钙素原指导的抗生素停用缩短抗生素使用时长(均数差1.31天,95%CI -2.27至-0.35,I²=93%,低确定性)。
- 在脓毒症亚组中未观察到生存获益(10项RCT,RR 0.94,95%CI 0.85-1.03,I²=0%)。
- 在无企业赞助的研究中未观察到生存获益(9项RCT,RR 0.98,95%CI 0.87-1.10,I²=0%)。
- 在高方案依从性研究(5项RCT,RR 0.93,95%CI 0.71-1.22,I²=0%)及不含C反应蛋白的算法研究(8项RCT,RR 0.96,95%CI 0.87-1.06,I²=0%)中均未观察到生存获益。
适用人群与场景
- 重症成人(5,158例随机,5,000例分析),来自16项随机对照试验。
研究设计与关键结果
- 研究设计:系统评价与Meta分析,检索PubMed、Embase、Scopus、Web of Science和CENTRAL,从建库至2018年7月23日,无语言限制,纳入报告生存或抗生素时长的随机对照试验。
- 主要结果:降钙素原指导的抗生素停用与死亡率降低相关(16项RCT,RR 0.89,95%CI 0.83-0.97,I²=0%,低确定性);仅1项研究以死亡为主要结局。
- 亚组分析:脓毒症亚组未观察到生存获益(10项RCT,RR 0.94,95%CI 0.85-1.03,I²=0%);无企业赞助研究未观察到生存获益(9项RCT,RR 0.98,95%CI 0.87-1.10,I²=0%);高方案依从性研究未观察到生存获益(5项RCT,RR 0.93,95%CI 0.71-1.22,I²=0%);不含C反应蛋白的算法研究未观察到生存获益(8项RCT,RR 0.96,95%CI 0.87-1.06,I²=0%)。
- 次要结果:降钙素原指导的抗生素停用缩短抗生素使用时长(均数差1.31天,95%CI -2.27至-0.35,I²=93%,低确定性)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(16项随机对照试验),采用随机效应模型合并数据,使用Cochrane偏倚风险工具评估研究质量,使用GRADEpro进行证据分级。
- 证据等级:死亡率结局为低确定性证据,抗生素使用时长为低确定性证据;存在高偏倚风险。
- 局限:原文报告高偏倚风险;仅1项研究以死亡为主要结局;死亡率获益主要见于方案依从性不高及降钙素原联合C反应蛋白算法的研究;需要以死亡为主要结局的精心设计研究来解决该问题。
对床旁实践的改变
- 在重症成人中,降钙素原指导的抗生素停用与死亡率降低及抗生素使用时长缩短相关,但证据为低确定性且高偏倚风险。
- 该生存获益主要在方案依从性不高及降钙素原联合C反应蛋白算法的研究中观察到,在脓毒症亚组、无企业赞助研究、高方案依从性研究及不含C反应蛋白的算法中未观察到。
- 作者认为,需要以死亡为主要结局的精心设计的研究来回答该问题。
指南或共识出处
- 国际前瞻性系统评价注册库(PROSPERO);注册号:CRD42016049715。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Procalcitonin (PCT)-guided antibiotic discontinuation appears to decrease antibiotic use in critically ill patients, but its impact on survival remains less certain.
METHODS: We searched PubMed, Embase, Scopus, Web of Science, and CENTRAL for randomized controlled trials (RCTs) of PCT-guided antibiotic discontinuation in critically ill adults reporting survival or antibiotic duration. Searches were conducted without language restrictions from inception to July 23, 2018. Two reviewers independently conducted all review stages; another adjudicated differences. Data were pooled using random-effects meta-analysis. Study quality was assessed with the Cochrane risk of bias tool, and evidence was graded using GRADEpro.
RESULTS: Among critically ill adults (5,158 randomized; 5,000 analyzed), PCT-guided antibiotic discontinuation was associated with decreased mortality (16 RCTs; risk ratio [RR], 0.89; 95% CI, 0.83-0.97; I2 = 0%; low certainty). Death was the primary outcome in only one study and a survival benefit was not observed in the subset specified as sepsis (10 RCTs; RR, 0.94; 95% CI, 0.85-1.03; I2 = 0%), those without industry sponsorship (nine RCTs; RR, 0.98; 95% CI, 0.87-1.10; I2 = 0%), high PCT-guided algorithm adherence (five RCTs; RR, 0.93; 95% CI, 0.71-1.22; I2 = 0%), and PCT-guided algorithms without C-reactive protein (eight RCTs; RR, 0.96; 95% CI, 0.87-1.06; I2 = 0%). PCT-guided antibiotic discontinuation decreased antibiotic duration (mean difference, 1.31 days; 95% CI, -2.27 to -0.35; I2 = 93%) (low certainty).
CONCLUSIONS: Our findings of increased survival and decreased antibiotic utilization associated with PCT-guided antibiotic discontinuation represent low-certainty evidence with a high risk of bias. This relationship was primarily observed in studies without high protocol adherence and in studies with algorithms combining PCT and C-reactive protein. Properly designed studies with mortality as the primary outcome are needed to address this question.
TRIAL REGISTRY: International Prospective Register of Systematic Reviews (PROSPERO); No.: CRD42016049715; URL: http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42016049715.
参考来源
- Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. Chest. 2019. PMID: 30772386. doi:10.1016/j.chest.2018.12.029
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。